查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840693

末期腎病市場按治療方式、存取類型和最終用戶分類 - 全球預測 2025-2032 年

End Stage Renal Disease Market by Treatment Modality, Access Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，末期腎臟病市場規模將達到 1,649.7 億美元，複合年成長率為 15.22%。

主要市場統計數據
基準年 2024 530.9億美元
預計年份：2025年 610.4億美元
預測年份：2032年 1649.7億美元
複合年成長率 (%) 15.22%

全面介紹正在再形成末期腎臟病護理服務和相關人員優先事項的不斷變化的臨床和營運動態。

末期腎病 (ESRD) 涉及臨床、營運和經濟等諸多複雜挑戰，影響整個醫療保健系統、醫療服務網路和患者群體。病患族群老化，且常伴隨多種併發症，使得治療方法選擇更加複雜，也推動了對整合式醫療服務路徑的需求。同時，透析方法、血管通路、移植通訊協定和數位療法等方面的技術進步正在重塑臨床決策和醫療服務模式。這些變化既為臨床醫生、採購團隊、製造商和支付方帶來了機遇，也帶來了壓力，他們必須在臨床療效、可負擔性和可及性之間取得平衡。

近年來，患者的偏好已轉向以最大限度提高生活品質和最大限度減少干擾為導向的護理，這促使人們對中心護理和居家護理進行策略性重新評估。監管挑戰和報銷框架也開始反映這一轉變，激勵那些能夠展現臨床療效和成本控制的模式和服務設計。同時，勞動力短缺和供應鏈脆弱性迫使醫療服務提供者和供應商獎勵其在採購、物流和培訓方面的投入。因此，相關人員越來越重視那些能夠提供臨床可靠性、靈活的交付模式和全面支援服務的解決方案。

本執行摘要概述了影響末期腎病 (ESRD) 診療的關鍵趨勢和策略意義。它重點闡述了臨床創新、營運韌性和相關人員協作之間的交集，並組裝了領導者必須解答的問題，以維持為日益成長且病情複雜的患者群體提供高品質的診療服務。本概要著重於以病人為中心的診療方法和系統層面的效率提升，為領導者在應對短期挑戰的同時，確保其機構在臨床和經濟效益方面持續保持領先地位提供了切實可行的指導。

識別末期腎臟病護理中推動模式轉變、供應鏈韌性、勞動力重組和以患者為中心的創新的關鍵系統轉型

除了臨床療效的逐步提升，末期腎病（ESRD）領域正在經歷一系列變革性轉變，這些轉變正在重新定義醫療模式和相關人員關係。技術創新加速了居家治療模式和遠端監測平台的普及，減輕了患者的出行負擔，並透過持續的數據流實現了早期療育。同時，政策轉向以以金額為準為導向，使得醫療協調、依從性支援和療效評估在醫療服務提供者合約和報銷談判中發揮越來越重要的作用。這些因素共同推動著更分散化、以病人為中心的醫療模式的形成。

勞動力壓力和臨床醫生角色的演變也在重塑營運模式。腎臟病團隊正透過跨學科診療路徑調整營運，並擴大護理師主導和遠端醫療主導，以維持醫療服務的可及性和品質。供應鏈韌性已成為一項核心策略重點，推動對本地製造能力、多元化供應商網路以及能夠抵禦地緣政治和物流衝擊的庫存管理系統的投資。此外，血管通路技術和移植管理的技術創新正在改變患者的長期治療軌跡，影響透析中心和移植計畫的容量規劃。

最後，老年人及其看護者數位素養的提升正在迅速提高患者的參與度和共同決策能力。將易用性、教育和心理社會支持融入產品和服務設計的醫療機構和供應商，正在獲得更高的患者共用和更好的治療效果。總而言之，這些轉變代表著一個正在向整合式照護路徑、技術賦能的居家養老選擇以及風險共擔機制邁進的生態系統，這些機制獎勵以患者為中心的指標取得顯著改善。

分析2025年關稅如何重塑末期腎病（ESRD）照護籌資策略、生產佈局、供應鏈風險管理和臨床資本規劃。

美國將於2025年實施關稅，這將改變醫療設備、耗材和藥品供應鏈的成本結構和籌資策略，對末期腎臟病（ESRD）相關人員產生重大的下游影響。進口關稅影響了透析設備、耗材和血管通路裝置的採購決策，迫使製造商和醫療服務提供者重新評估其區域製造地和長期供應商關係。為此，許多公司加快了近岸外包的步伐，並擴大了與國內製造外包的夥伴關係，以降低跨境價格波動和前置作業時間風險。

隨著總成本估算變得更加難以預測，採購團隊面臨著更為複雜的挑戰，導致其關注點從單位成本轉向更廣泛的採購指標，例如交付可靠性、品質保證和供應商多元化。這種轉變也影響了他們與設備製造商和分銷商的談判能力，後者擴大將服務和維護合約捆綁在一起，以確保穩定的收入來源，同時為客戶提供可預測的生命週期支援。同時，由於需要評估不斷上漲的設備和耗材成本的財務影響，臨床醫生和醫院管理人員也受到了採購週期變化和資本投資延遲等間接影響。

在技​​術創新方面，研發藍圖進行了調整，優先發展本地組裝的模組化平台，以減輕關稅的影響並支持靈活的生產規模化。產業協會和醫療系統領導者積極倡導對關鍵醫療用品實施關稅豁免和定向減免，以確保弱勢患者群體能夠獲得價格合理的醫療服務，相關部門對該計畫的參與度也隨之提高。整體而言，2025年關稅的累積影響促使策略規劃重新聚焦於供應鏈的靈活性、採購的精細化以及計畫倡導，以保障末期腎臟病患者的持續治療。

透過細分市場分析，主導了解治療方式、血管通路和護理環境之間的相互依存關係如何決定末期腎臟病服務的臨床路徑、營運需求和投資重點。

透過細分獲得的洞見揭示了治療方法選擇、血管通路和護理環境如何相互作用，從而塑造臨床路徑和營運需求。治療方式包括血液透析機、腹膜透析和腎臟移植，其中血液透析機可細分為居家透析和中心透析模式，而腹膜透析則分為持續性非臥床腹膜透析和持續性循環腹膜透析。這些細分會影響採購、培訓和依從性支援的優先事項，因為每種治療方式及其子模式對設備、病患教育、監測基礎設施和長期臨床追蹤的需求各不相同。

血管存取類型分類有助於明確動靜脈瘻管、中央靜脈導管和人工血管等不同選擇在臨床和操作層面的權衡取捨。血管通路的選擇直接影響併發症發生率、住院風險和維護通訊協定的強度，進而影響人員配置模式和輔助服務需求。因此，醫療機構必須使其血管通路方案與治療策略相匹配，以最佳化患者預後並減少不必要的醫療資源消耗。

這項調查的最終用戶群體——透析中心、居家照護機構和醫院——揭示了各自不同的營運模式和服務期望。透析中心強調吞吐量、標準化通訊協定和打包服務，而居家照護則優先考慮患者培訓、遠端監測和物流供應。醫院需要整合的急性護理路徑和快速併發症處理機制。了解這些群體之間的互動方式，有助於管理者設計針對特定治療模式的服務包，協調臨床醫生培訓，並優先考慮能夠提升臨床療效和患者體驗的投資。

對美洲、歐洲、中東和非洲以及亞太地區的動態如何影響末期腎臟病（ESRD）護理模式的採用、基礎設施投資和政策進行區域分析。

區域動態對末期腎病（ESRD）的醫療服務選擇、投資重點和監管方式有顯著影響。美洲的醫療體系涵蓋單一支付方和混合支付方，這影響報銷方式、居家治療方法的普及率以及私人機構參與醫療服務的程度。儘管該地區在醫療設備應用和遠端醫療整合方面往往處於領先地位，但農村地區也面臨勞動力短缺的困境，這限制了醫療服務的可近性。政策辯論和支付方的舉措影響著國家和地區層面的資本配置和基於價值的醫療獎勵。

在歐洲、中東和非洲，法規環境和基礎設施能力的差異導致了不同的應用模式。高所得的歐洲市場擁有嚴格的臨床標準和完善的報銷機制，支持創新技術的應用和健全的移植項目；而歐洲、中東和非洲的新興市場則面臨基礎設施不足、透析能力有限和資金籌措限制等問題，因此需要可擴展且資源成本低的解決方案。跨境採購和區域製造中心在提高供應可靠性和成本效益方面發揮著日益重要的作用。

亞太地區擁有快速成長的需求、多元化的支付方結構以及強大的製造業基礎，這為國內生產和出口提供了有力支撐。該地區許多醫療系統正在投資居家醫療模式和數位化平台，以擴大都市區和城郊人口的醫療服務覆蓋範圍，同時兼顧擴大移植基礎設施和人才隊伍建設的需求。該地區各相關人員必須使其策略與當地政策促進因素、基礎設施現狀和人口趨勢相契合，以確保服務的永續提供和患者公平獲得醫療服務。

深入剖析了該公司如何透過結合產品創新、整合服務、供應鏈敏捷性和卓越的監管能力，引領末期腎臟病醫療保健的策略。

活躍於末期腎病 (ESRD) 生態系統中的各公司之間的競爭與合作正在塑造產品設計、服務交付模式和售後支援策略。產業參與者正日益從純粹以產品為中心的模式轉向整合服務包，將設備、耗材、培訓、維護和數位化監控相結合。這種轉變響應了醫療服務提供者對可預測結果的需求以及支付方對可衡量、以價值為導向的指標的關注。因此，能夠提供可靠的臨床證據、全面的培訓計劃和可靠的現場服務能力的公司在合約談判中擁有明顯的優勢。

隨著企業尋求加速漸進式創新產品的上市速度並共用研發風險，策略夥伴關係、授權協議和聯合開發舉措正變得越來越普遍。製造外包和本地組裝策略也在不斷擴展，以減輕關稅的影響並縮短前置作業時間。投資於互通軟體和開放資料方法的企業可以參與醫療網路和人口健康舉措。此外，售後服務——從耗材供應物流到預測性維護和遠端故障排除——正在成為影響客戶維繫和終身價值的關鍵差異化因素。

最後，那些優先考慮監管合規和衛生經濟學證據產生的公司將更容易獲得優質採購管道，並與支付者進行更有效的談判。最具韌性的公司將強大的臨床研發管線、可擴展的服務模式和靈活的供應鏈結合，以滿足不同醫療機構中醫療服務提供者和患者不斷變化的需求。

為領導者提供行動建議，以擴大居家治療模式、加強供應鏈、推進數位整合並影響政策，從而確保末期腎病 (ESRD) 的長期療效。

行業領導者必須採取果斷而協調的措施，將不斷變化的證據和營運壓力轉化為永續的競爭優勢。首先，各機構應優先發展居家治療模式，並輔以完善的病患教育和遠距監測項目，以符合病患偏好並減輕系統層面的負擔。此類投資應輔以清晰的臨床路徑和結果指標，從而實現持續改善。其次，企業和醫療服務提供者必須透過近岸外包、多通路採購和有效的本地夥伴關係來實現供應鏈多元化，以降低關稅波動和物流中斷帶來的風險。

第三，相關人員可互通的數位平台，整合設備遠端檢測、電子健康記錄和病患報告結果，以支援主動式照護管理和基於價值的合約。第四，勞動力發展至關重要。應投資於可擴展的培訓項目，提升護理師、技師和護理協調員的技能，以支援居家護理和遠距遠端醫療的工作流程。第五，應積極與政策制定者和支付方合作，制定報銷框架，獎勵在以病人為中心的結果、醫療服務可近性和長期成本效益方面取得顯著進步的措施。最後，應採取組合式創新方法，平衡短期營運改善與對移植支援、血管通路創新和微創技術的長期投資。

透過協調一致地實施這些行動，領導者可以改善臨床結果，保護利潤免受外部衝擊，並使他們的組織在護理模式不斷發展的過程中保持持續的領先地位。

採用嚴謹的多方法調查方法方法，結合相關人員參與、文獻回顧、用例分析、情境測試和專家諮詢檢驗。

這些研究成果基於一種多方法研究策略，旨在整合臨床證據、營運實踐和政策制定。一級資訊來源包括與臨床醫生、供應鏈經理、醫療系統高管和支付方舉行的結構化會議，以了解他們對治療方式採納、准入管理和採購挑戰的現場觀點。二級資訊來源包括同行評審的臨床文獻、監管文件、臨床實踐指南和公共文件，以檢驗臨床療效和監管趨勢。這些資訊被納入定性綜合和主題分析，重點關注患者就診路徑、器械生命週期管理和服務模式經濟學。

為確保研究的穩健性，調查方法納入了針對示範性醫療服務體系和供應商的用例，這些體系和供應商已成功實施了家庭透析治療規模化、整合遠端監測和彈性籌資策略。情境分析考慮了各種可能的供應鏈和政策發展趨勢，以對策略選擇進行壓力測試。在資料完整性方面，研究對採購和監管資料點進行了交叉檢驗，仔細記錄了訪談通訊協定，並根據相關人員的回饋不斷調整，以最大限度地減少偏差，確保研究結果在不同醫療環境中的適用性。

這種多層次的方法將深入的定性見解與嚴謹的文獻證據相結合，為尋求改善末期腎臟病 (ESRD) 患者治療效果和營運韌性的臨床醫生、管理者和商業性相關人員提供可操作的見解。

總結性綜述強調了臨床創新、營運韌性和協作策略之間的相互作用，以改善末期腎病 (ESRD) 治療的效果和可及性。

總體而言，末期腎病治療正處於曲折點，臨床創新、政策獎勵和營運限制正在交匯融合，重塑服務的提供和資金籌措方式。對居家醫療的日益重視，以及血管通路和監測技術的進步，為改善病患體驗和治療效果提供了實際的機會。然而，這些機會也伴隨著持續存在的挑戰，包括醫護人員短缺、基礎設施不足和供應鏈脆弱性，這些都需要製定周密的應對策略。

積極調整採購、臨床路徑和數位化整合的領導者將更有能力應對外部衝擊並實現以金額為準目標。同樣重要的是，需要採取協作方式，將臨床醫生、支付方、製造商和患者權益倡導者聚集在一起，共同設計可在各種環境下推廣的實用解決方案。透過專注於模組化、可互通的解決方案，加強區域製造商和供應商網路，並嚴格衡量以患者為中心的結果，相關人員可以在保持卓越臨床水平的同時，提高醫療服務的可及性和韌性。

推動這項工作需要各方共同投入和嚴格執行。將這些洞見融入策略規劃的機構，不僅能改善末期腎病患者的護理，還能建構永續的商業模式，抵禦市場和政策的波動。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將遠距遠端醫療應用於居家血液透析機可以提高患者依從性並降低住院率
  • 穿戴式人工腎臟的出現，旨在為門診透析患者改善活動能力和生活品質。
  • 擴大精準醫療生物標記的應用範圍，以預測殘餘腎功能下降並制定個人化治療方法
  • 為了滿足不斷成長的需求並降低新興市場的醫療保健成本，對腹膜透析基礎設施的投資正在增加。
  • 將人工智慧演算法整合到透析設備中，用於即時監測和預測性維護警報

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章 末期腎病市場：依治療方式分類

  • 血液透析機
    • 在家裡
    • 設施內部
  • 腹膜透析
    • 持續性攜帶式腹膜透析
    • 連續循環腹膜透析
  • 移植
    • 已故捐贈者
    • 活體捐贈者

9. 依存取類型分類的末期腎病市場

  • 動靜脈瘻管
  • 中央靜脈導管
  • 合成接枝

第10章 以最終用戶分類的末期腎病市場

  • 透析中心
  • 居家照護
  • 醫院

第11章 各地區末期腎病市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 末期腎病市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國末期腎病市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Fresenius Medical Care AG & Co. KGaA
    • DaVita Inc.
    • Baxter International Inc.
    • B. Braun Melsungen AG
    • Nipro Corporation
    • NxStage Medical, Inc.
    • US Renal Care, Inc.
    • Satellite Healthcare, Inc.
    • Dialysis Clinic, Inc.
    • Jafron Biomedical Co., Ltd.
Product Code: MRR-DA46DD749C68

The End Stage Renal Disease Market is projected to grow by USD 164.97 billion at a CAGR of 15.22% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 53.09 billion
Estimated Year [2025] USD 61.04 billion
Forecast Year [2032] USD 164.97 billion
CAGR (%) 15.22%

Comprehensive introduction to the evolving clinical and operational dynamics that are reshaping End Stage Renal Disease care delivery and stakeholder priorities

End Stage Renal Disease (ESRD) poses a complex blend of clinical, operational, and economic challenges that reverberate across healthcare systems, provider networks, and patient communities. Patient populations are aging and increasingly present multiple comorbidities, which complicates treatment selection and intensifies demand for integrated care pathways. Concurrently, technological advances in dialysis modalities, vascular access, transplantation protocols, and digital therapeutics are reshaping clinical decision-making and care delivery models. These changes create both opportunities and pressures for clinicians, procurement teams, manufacturers, and payers who must balance clinical outcomes with affordability and access.

In recent years, patient preferences have shifted toward treatments that maximize quality of life and minimize disruption, prompting a strategic reassessment of in-center care versus home-based therapies. Regulatory agendas and reimbursement frameworks have begun to reflect that shift, incentivizing modalities and service designs that demonstrate clinical effectiveness and cost containment. At the same time, workforce constraints and supply chain fragilities are forcing providers and vendors to rethink sourcing, logistics, and training investments. As a result, stakeholders increasingly prioritize solutions that deliver clinical reliability, flexible delivery models, and integrated support services.

This executive summary synthesizes the essential trends and strategic implications shaping ESRD care. It emphasizes the intersection of clinical innovation, operational resilience, and stakeholder alignment, and it frames the questions leaders must answer to sustain high-quality care for growing, complex patient cohorts. By foregrounding patient-centric approaches and system-level efficiencies, the summary offers a practical orientation for leaders seeking to navigate near-term disruptions while positioning their organizations for sustained clinical and economic performance.

Identification of the major systemic transformations in ESRD care that are driving modality shifts, supply chain resilience, workforce reconfiguration, and patient-centered innovation

The ESRD landscape is undergoing a sequence of transformative shifts that extend beyond incremental clinical improvements to redefine care models and stakeholder relations. Technological innovation has accelerated the adoption of home modalities and remote monitoring platforms, reducing patient travel burden and enabling earlier intervention through continuous data streams. Simultaneously, policy shifts emphasize value-based outcomes, which elevates the role of care coordination, adherence support, and outcome measurement in provider contracting and reimbursement conversations. These forces together are driving a more decentralized, patient-centered model of care.

Workforce pressures and evolving clinician roles are also reshaping operational models. Nephrology teams are reallocating tasks through multidisciplinary care pathways and expanding nurse-led and telehealth-driven services to maintain access and quality. Supply chain resilience has become a core strategic priority, prompting investment in local manufacturing capabilities, diversified supplier networks, and inventory management systems that can withstand geopolitical and logistic shocks. Moreover, innovation in vascular access techniques and transplant management is altering long-term patient trajectories, thereby influencing capacity planning for dialysis centers and transplant programs.

Finally, patient engagement and shared decision-making are advancing rapidly as digital literacy increases among older adults and caregivers. Providers and vendors that embed usability, education, and psychosocial supports into product and service designs achieve higher adherence and better outcomes. Taken together, these shifts indicate an ecosystem moving toward integrated care pathways, technology-enabled home options, and risk-sharing arrangements that reward demonstrable improvements in patient-centric metrics.

Analysis of how 2025 tariff measures have reshaped procurement strategies, manufacturing footprints, supply chain risk management, and clinical capital planning for ESRD care

The implementation of United States tariffs in 2025 has created material downstream effects for ESRD stakeholders by altering cost structures and procurement strategies across the device, consumable, and pharmaceutical supply chains. Import levies have influenced sourcing decisions for dialysis machines, disposables, and access devices, prompting manufacturers and providers to re-evaluate regional manufacturing footprints and long-term supplier relationships. In response, many organizations accelerated nearshoring initiatives and expanded partnerships with domestic contract manufacturers to mitigate exposure to cross-border price volatility and lead-time risks.

Procurement teams faced greater complexity as total landed costs became less predictable, which in turn shifted emphasis from unit price alone to broader procurement metrics such as delivery reliability, quality assurance, and supplier diversification. These shifts also affected negotiation dynamics with original equipment manufacturers and distributors, who increasingly offered bundled service and maintenance contracts to preserve stable revenue streams while providing clients with predictable lifecycle support. In parallel, clinicians and hospital administrators experienced indirect impacts through altered purchasing cycles and delayed capital investments, as organizations assessed the financial implications of higher equipment and consumable costs.

On the innovation front, R&D roadmaps adjusted to prioritize modular, locally assemblable platforms that reduce tariff exposure and support flexible production scaling. Policy engagement intensified as industry groups and health system leaders advocated for tariff exemptions or targeted relief for critical medical supplies to preserve access and affordability for vulnerable patient populations. Overall, the cumulative impact of 2025 tariff measures has been to refocus strategic planning on supply chain agility, procurement sophistication, and policy advocacy to safeguard continuity of care for ESRD patients.

Segment-driven insights into how modality, vascular access, and care setting interdependencies define clinical pathways, operational demands, and investment priorities for ESRD services

Insights derived from segmentation reveal how modality choice, vascular access, and care setting interlock to shape clinical pathways and operational requirements. Treatment Modality considerations encompass Hemodialysis, Peritoneal Dialysis, and Transplant, with Hemodialysis further differentiated between Home and Incenter delivery models, and Peritoneal Dialysis separated into Continuous Ambulatory Peritoneal Dialysis and Continuous Cycling Peritoneal Dialysis; Transplant pathways distinguish patient journeys by Deceased Donor and Living Donor sources. These distinctions matter because each modality and sub-modality drives different needs for capital equipment, patient education, monitoring infrastructure, and long-term clinical follow-up, thereby influencing procurement, training, and adherence support priorities.

Access Type segmentation clarifies clinical and logistical trade-offs across Arteriovenous Fistula, Central Venous Catheter, and Synthetic Graft options. Vascular access choice directly affects complication rates, hospitalization risk, and the intensity of maintenance protocols, which in turn shapes staffing models and ancillary service demand. Providers must therefore align vascular access programs with modality strategies to optimize patient outcomes and reduce avoidable utilization.

End User segmentation, which examines Dialysis Centers, Home Care Settings, and Hospitals, highlights divergent operational models and service expectations. Dialysis centers emphasize throughput, standardized protocols, and bundled service offerings, whereas home care settings prioritize patient training, remote monitoring, and supply delivery logistics. Hospitals require integrated acute care pathways and rapid escalation mechanisms for complications. Understanding how these segments interact enables leaders to design modality-specific service bundles, tailor clinician training, and prioritize investments that support both clinical effectiveness and patient experience.

Regional analysis of how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics influence adoption, infrastructure investment, and policy-driven ESRD care models

Regional dynamics materially influence care delivery choices, investment priorities, and regulatory approaches to ESRD management. In the Americas, healthcare systems vary from single-payer to mixed models, which affects reimbursement levers, adoption rates of home modalities, and private-sector participation in service delivery. This region often leads in device adoption and telehealth integration but also faces concentrated workforce shortages in rural areas that constrain access. Policy debates and payer initiatives shape capital allocation and incentives for value-based care across national and subnational jurisdictions.

Europe, Middle East & Africa present a heterogeneous mix of regulatory environments and infrastructure capacity that drives divergent adoption patterns. In higher-income European markets, rigorous clinical standards and comprehensive reimbursement frameworks support innovation uptake and robust transplantation programs, while emerging EMEA markets confront infrastructure gaps, limited dialysis capacity, and financing constraints that require scalable, low-resource solutions. Cross-border procurement and regional manufacturing hubs play increasing roles in improving supply reliability and cost efficiency.

Asia-Pacific combines rapidly growing demand, diverse payer structures, and a strong manufacturing base that supports both domestic production and export opportunities. Many health systems in the region are investing in home care models and digital platforms to extend access across urban and peri-urban populations, while also balancing the need to expand transplant infrastructure and workforce training. In each region, stakeholders must tailor strategies to local policy drivers, infrastructure realities, and demographic trends to ensure sustainable service delivery and equitable patient access.

Insightful overview of company strategies that blend product innovation, integrated services, supply chain agility, and regulatory excellence to lead in ESRD care

Competitive and collaborative behaviors among companies active in the ESRD ecosystem are shaping product design, service delivery models, and aftermarket support strategies. Industry participants are increasingly moving from a purely product-centric orientation to integrated service bundles that combine devices, consumables, training, maintenance, and digital monitoring. This shift responds to provider demand for predictable outcomes and to payer interest in measurable, value-based metrics. As a result, firms that can demonstrate robust clinical evidence, comprehensive training programs, and reliable field service capabilities gain a distinct advantage in contracting discussions.

Strategic partnerships, licensing arrangements, and co-development initiatives are becoming more common as companies seek to accelerate time-to-market for incremental innovations while sharing development risk. Contract manufacturing and regional assembly strategies are also expanding to reduce tariff exposure and improve lead times. Firms that invest in interoperable software and open-data approaches position themselves to participate in care networks and population health initiatives. Additionally, aftermarket services-ranging from consumable supply logistics to predictive maintenance and remote troubleshooting-are emerging as meaningful differentiators that influence customer retention and lifetime value.

Finally, companies that prioritize regulatory excellence and health economics evidence generation improve their access to premium procurement pathways and payer negotiations. The most resilient firms pair strong clinical pipelines with scalable service models and agile supply chains to meet the evolving needs of providers and patients in diverse care settings.

Actionable recommendations for leaders to scale home modalities, strengthen supply chains, advance digital integration, and influence policy to secure long-term ESRD performance

Industry leaders must take decisive, coordinated steps to translate evolving evidence and operational pressures into sustainable competitive advantage. First, organizations should prioritize expansion of home-based modalities alongside robust patient education and remote monitoring programs to align with patient preferences and reduce system-level burdens. Such investments should be accompanied by clear clinical pathways and outcome metrics that enable continual improvement. Second, firms and providers must diversify supply chains through nearshoring, multi-sourcing, and validated local partnerships to reduce exposure to tariff fluctuations and logistic disruptions.

Third, stakeholders should pursue interoperable digital platforms that integrate device telemetry, electronic health records, and patient-reported outcomes to support proactive care management and value-based contracting. Fourth, workforce development is critical: invest in scalable training programs that upskill nurses, technicians, and care coordinators to support home therapies and telehealth-enabled workflows. Fifth, engage proactively with policymakers and payers to shape reimbursement frameworks that reward demonstrated improvements in patient-centered outcomes, access, and long-term cost efficiencies. Finally, adopt a portfolio approach to innovation that balances near-term operational improvements with longer-term investments in transplant support, vascular access innovation, and minimally invasive technologies.

By implementing these actions in a coordinated manner, leaders can improve clinical outcomes, protect margins against external shocks, and position their organizations for sustained leadership as care models continue to evolve.

Explanation of a rigorous multi-method research methodology combining primary stakeholder engagement, literature synthesis, case studies, scenario testing, and expert advisory validation

The research underpinning these insights draws on a multi-method approach designed to triangulate clinical evidence, operational practice, and policy developments. Primary sources included structured engagements with clinicians, supply chain managers, health system executives, and payers to capture frontline perspectives on modality adoption, access management, and procurement challenges. Secondary sources encompassed peer-reviewed clinical literature, regulatory filings, clinical practice guidelines, and public policy documents to validate clinical efficacy and regulatory trajectories. These inputs informed qualitative synthesis and thematic analysis focused on patient pathways, device life-cycle management, and service model economics.

To ensure robustness, the methodology incorporated targeted case studies of exemplar provider systems and suppliers that have implemented home dialysis scale-ups, integrated remote monitoring, or resilient procurement strategies. Scenario analysis explored plausible supply chain and policy developments to stress-test strategic options, while an advisory panel of clinical and operational experts reviewed findings and recommended refinements. Data integrity measures included cross-validation of procurement and regulatory data points, careful documentation of interview protocols, and iterative reconciliation of stakeholder feedback to minimize bias and ensure relevance across care settings.

This layered approach balances deep qualitative insight with rigorous documentary evidence, producing findings that are actionable for clinicians, administrators, and commercial stakeholders seeking to improve patient outcomes and operational resilience in ESRD care.

Conclusive synthesis emphasizing the interplay of clinical innovation, operational resilience, and collaborative strategies required to improve ESRD care outcomes and access

In synthesis, End Stage Renal Disease care is at an inflection point where clinical innovation, policy incentives, and operational constraints converge to reshape how services are delivered and financed. The growing emphasis on home-based modalities, coupled with advances in vascular access and monitoring technologies, creates tangible opportunities to improve patient experience and outcomes. However, these opportunities coexist with persistent challenges, including workforce shortages, infrastructure gaps, and supply chain vulnerabilities that require deliberate mitigation strategies.

Leaders who proactively realign procurement, clinical pathways, and digital integration will be better positioned to manage external shocks and deliver on value-based objectives. Equally important is the need for collaborative approaches that bring together clinicians, payers, manufacturers, and patient advocates to design pragmatic solutions that scale across diverse settings. By focusing on modular, interoperable solutions, strengthening local manufacturing and supplier networks, and rigorously measuring patient-centered outcomes, stakeholders can enhance access and resilience while preserving clinical excellence.

Ultimately, the pathway forward requires coordinated investment and disciplined execution. Organizations that integrate these insights into strategic plans will not only improve care for patients living with ESRD but also create sustainable operating models that withstand market and policy volatility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of home hemodialysis driven by telehealth integration to improve patient adherence and reduce hospitalization rates
  • 5.2. Emergence of wearable artificial kidneys designed for ambulatory dialysis to enhance patient mobility and quality of life
  • 5.3. Increasing utilization of precision medicine biomarkers to predict residual renal function decline and personalize treatment regimens
  • 5.4. Rising investments in peritoneal dialysis infrastructure to address increasing demand in emerging markets and reduce healthcare costs
  • 5.5. Integration of artificial intelligence algorithms in dialysis machines for real time monitoring and predictive maintenance alerts

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. End Stage Renal Disease Market, by Treatment Modality

  • 8.1. Hemodialysis
    • 8.1.1. Home
    • 8.1.2. Incenter
  • 8.2. Peritoneal Dialysis
    • 8.2.1. Continuous Ambulatory Peritoneal Dialysis
    • 8.2.2. Continuous Cycling Peritoneal Dialysis
  • 8.3. Transplant
    • 8.3.1. Deceased Donor
    • 8.3.2. Living Donor

9. End Stage Renal Disease Market, by Access Type

  • 9.1. Arteriovenous Fistula
  • 9.2. Central Venous Catheter
  • 9.3. Synthetic Graft

10. End Stage Renal Disease Market, by End User

  • 10.1. Dialysis Centers
  • 10.2. Home Care Settings
  • 10.3. Hospitals

11. End Stage Renal Disease Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. End Stage Renal Disease Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. End Stage Renal Disease Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Fresenius Medical Care AG & Co. KGaA
    • 14.3.2. DaVita Inc.
    • 14.3.3. Baxter International Inc.
    • 14.3.4. B. Braun Melsungen AG
    • 14.3.5. Nipro Corporation
    • 14.3.6. NxStage Medical, Inc.
    • 14.3.7. U.S. Renal Care, Inc.
    • 14.3.8. Satellite Healthcare, Inc.
    • 14.3.9. Dialysis Clinic, Inc.
    • 14.3.10. Jafron Biomedical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. END STAGE RENAL DISEASE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. END STAGE RENAL DISEASE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. END STAGE RENAL DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 231. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 232. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 233. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. GCC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GCC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GCC END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 240. GCC END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 241. GCC END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 242. GCC END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 243. GCC END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 244. GCC END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 245. GCC END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 246. GCC END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 247. GCC END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. GCC END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. GCC END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. GCC END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 268. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 269. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 270. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 271. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 272. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 273. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 274. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 275. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. G7 END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. G7 END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. G7 END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 282. G7 END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 283. G7 END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 284. G7 END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 285. G7 END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 286. G7 END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 287. G7 END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 288. G7 END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 289. G7 END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. G7 END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. G7 END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. G7 END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. NATO END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. NATO END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. NATO END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 296. NATO END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 297. NATO END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 298. NATO END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 299. NATO END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 300. NATO END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 301. NATO END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 302. NATO END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 303. NATO END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. NATO END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. NATO END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. NATO END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 311. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 312. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 313. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 314. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 315. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 316. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 317. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. CANADA END STAGE RENAL